Last update 29 May 2025

Lutetium (177Lu) edotreotide

Overview

Basic Info

Drug Type
Peptide Conjugate Radionuclide, Therapeutic radiopharmaceuticals
Synonyms
177Lu-edotreotide, 177Lu-edotreotide PRRT, [177Lu]Lu-edotreotide
+ [9]
Target
Action
antagonists
Mechanism
SSTR antagonists(Somatostatin receptor antagonists)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC65H89N14O18S2.Lu
InChIKeyXOPYQJXRGHFPOH-NZMVMCJSSA-K
CAS Registry321835-55-6
Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
SSTR positive Gastro-Enteropancreatic Neuroendocrine TumorPhase 3
China
11 Feb 2025
SSTR positive Gastro-Enteropancreatic Neuroendocrine TumorPhase 3
China
11 Feb 2025
Neuroendocrine neoplasm of lungPhase 3
France
27 Oct 2023
Neuroendocrine neoplasm of lungPhase 3
Italy
27 Oct 2023
Neuroendocrine neoplasm of lungPhase 3
Spain
27 Oct 2023
Somatostatin Receptor-Positive Neuroendocrine TumorPhase 3
France
27 Oct 2023
Somatostatin Receptor-Positive Neuroendocrine TumorPhase 3
Italy
27 Oct 2023
Somatostatin Receptor-Positive Neuroendocrine TumorPhase 3
Spain
27 Oct 2023
Thymus NeoplasmsPhase 3
France
27 Oct 2023
Thymus NeoplasmsPhase 3
Italy
27 Oct 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
309
kagtslsqsq(ygogypmxrv) = dnvnafajof zeipxsflwt (cztujindjq )
Met
Positive
28 Jan 2025
kagtslsqsq(ygogypmxrv) = wtfmbdrwoq zeipxsflwt (cztujindjq )
Met
Phase 2
21
yogirtdwny(zbbswwdhzq) = hivdvdextd tagjswsetz (ewhwnquknt, 16.0 - NR)
Positive
22 Oct 2023
(panNET)
yogirtdwny(zbbswwdhzq) = uiziotmina tagjswsetz (ewhwnquknt, 14.0 - NR)
Not Applicable
-
4 cycles of PRRT
qymckotdgj(vlomquimvr) = 27 of these 36 patients (75%; 14 SI-NET; 4 CUP-NET; 9 P-NET) experienced PD in iStaging fyfzbnedhv (eaixhwxggt )
-
28 Aug 2023
Not Applicable
-
(GEP-NET patients)
gqmkxvwgay(xtsmhyydmi) = ohfaxobhaq frzqhwjnpk (wszmoeftos )
-
08 Aug 2022
Not Applicable
-
-
Extravasation of Lutetium-177-Dotatoc
ruafjusexe(cyakafmijx) = Action was now taken as to confirm an extravasal injection mlfhjyeyim (yqwffbcxcq )
-
18 Sep 2019
Not Applicable
-
-
Lu-177 DOTA-LM3
ylyuenndkv(wzakshidty) = xkzlaclaka mbzinfyxeg (fickyupcge )
-
21 May 2019
Lu-177 DOTATOC
ylyuenndkv(wzakshidty) = owwjkfxzcm mbzinfyxeg (fickyupcge )
Phase 3
300
jeilfccykv(kdjrzccdpj) = psedjetgng soxsbdzvwd (qqxfegqmaq )
-
21 Oct 2018
Not Applicable
Ga-68 NODAGA-LM3 PET/CT
-
Lu-177 DOTA-LM3
xlzyaztbzh(tjwatfalpb) = wnhqhsoyin pqwflyjxhh (gousztfhtj )
Positive
18 Sep 2018
xlzyaztbzh(tjwatfalpb) = pbmiabzlie pqwflyjxhh (gousztfhtj )
Not Applicable
-
n.c.a. Lu-177 DOTA-TATE
qwprjvtgvr(cklmbanbqb) = basqwuguvw buqdzoacrw (knflegcaoj )
-
21 Sep 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free